Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.
BRAFV600E mutation
Dabrafenib
Posterior pituitary tumor
TTF-1
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
20
09
2021
accepted:
03
01
2022
pubmed:
15
1
2022
medline:
28
4
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.
Identifiants
pubmed: 35029761
doi: 10.1007/s00701-022-05109-w
pii: 10.1007/s00701-022-05109-w
doi:
Substances chimiques
Imidazoles
0
Oximes
0
Protein Kinase Inhibitors
0
Thyroid Nuclear Factor 1
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
dabrafenib
QGP4HA4G1B
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
737-742Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Das L, Vaiphei K, Rai A et al (2021) Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. Endocr Connect 10(4):387–400. https://doi.org/10.1530/EC-20-0621
doi: 10.1530/EC-20-0621
pubmed: 33709954
pmcid: 8142326
Dawoud FM, Naylor RM, Giannini C, Swanson AA, Meyer FB, Uhm JH (2020) TTF-1 positive posterior pituitary tumor: limitations of current treatment and potential new hope in BRAF V600E mutation variants. Clin Neurol Neurosurg 196:106059. https://doi.org/10.1016/j.clineuro.2020.106059
doi: 10.1016/j.clineuro.2020.106059
pubmed: 32682222
Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019) Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review. Cancers 11(12):1950. https://doi.org/10.3390/cancers11121950
doi: 10.3390/cancers11121950
pmcid: 6966686
Hasegawa H, Van Gompel JJ, Oushy SH et al (2021) A comprehensive study of spindle cell oncocytoma of the pituitary gland: series of 6 cases and meta-analysis of 85 cases. World Neurosurg 149:e197–e216. https://doi.org/10.1016/j.wneu.2021.02.051
doi: 10.1016/j.wneu.2021.02.051
pubmed: 33610869
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8
doi: 10.1007/s00401-017-1769-8
pubmed: 28821944
Maraka S, Janku F (2018) BRAF alterations in primary brain tumors. Discov Med 26(141):51–60
pubmed: 30265855
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243. https://doi.org/10.1097/PAS.0b013e31829723e7
doi: 10.1097/PAS.0b013e31829723e7
Mete O, Lopes MB, Asa SL (2013) Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 37(11):1694–1699. https://doi.org/10.1007/s12022-017-9498-z
doi: 10.1007/s12022-017-9498-z
pubmed: 23887161
Miller MB, Bi WL, Ramkissoon LA, et al (2016) MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget 7(24):37054–37063. https://doi.org/10.18632/oncotarget.9244
Peuvrel L, Dréno B (2014) Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 15(5):425–444. https://doi.org/10.1007/s40257-014-0088-2
doi: 10.1007/s40257-014-0088-2
pubmed: 25117153
Roncaroli F, Chatterjee D, Giannini C et al (2020) Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF-1-positive sellar lesions. Neuropathol Appl Neurobiol 46(5):493–505. https://doi.org/10.1111/nan.12622
doi: 10.1111/nan.12622
pubmed: 32311761
Salge-Arrieta FJ, Carrasco-Moro R, Rodríguez-Berrocal V, Pian H, Martínez-San Millán JS, Iglesias P, Ley-Urzáiz L (2019) Clinical features, diagnosis and therapy of pituicytoma: an update. J Endocrinol Invest 42(4):371–384. https://doi.org/10.1007/s40618-018-0923-z
doi: 10.1007/s40618-018-0923-z
pubmed: 30030746
Sollfrank L, Lettmaier S, Erdmann M, Uslu U (2019) Panniculitis under successful targeted inhibition of the MAPK/ERK signaling pathway in a patient with BRAF V600E-mutated spindle cell oncocytoma of the pituitary gland. Anticancer Res 39(7):3955–3959. https://doi.org/10.21873/anticanres.13549
Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, Nasrallah MP (2019) Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol Commun 7(1):69. https://doi.org/10.1186/s40478-019-0722-6
doi: 10.1186/s40478-019-0722-6
pubmed: 31046843
pmcid: 6498683